Advertisement

Issue 1, Volume 128

Cover Figure: Central role of dematin in red cell membrane integrity. See the article by Lu et al.

WASHINGTON, July 7,  2016 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Gene disruption of dematin causes precipitous loss of erythrocyte membrane stability and severe hemolytic anemia
In a series of murine studies, Lu and colleagues uncover a previously unrecognized central role of the protein dematin in the unique organization of the erythrocyte membrane structure and the maintenance of red blood cell membrane integrity.

Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies
McKerrell and colleagues describe a novel next-generation sequencing–based platform for the identification of point mutations, common fusion genes, and copy number alterations in acute myeloid leukemia and myelodysplasia from a single genomic DNA sample.

Human neutrophil peptides inhibit cleavage of von Willebrand factor by ADAMTS13: a potential link of inflammation to TTP
Pillai and colleagues furnish novel insights revealing that human neutrophil peptides from activated neutrophils block interactions between ADAMTS13 and von Willebrand factor. These data suggest a new pathogenetic mechanism for the onset of acute acquired thrombotic thrombocytopenic purpura (TTP).

Metastasis: new functional implications of platelets and megakaryocytes
In a review, Leblanc and Peyruchaud discuss the recent advances in our knowledge of how platelets contribute to cancer metastasis and possible entry points for the development of new antimetastasis therapies.

Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease
In an important clinical study, Koreth et al report that interleukin-2 offers an effective treatment modality for chronic graft-versus-host disease in patients who have failed up to 2 prior lines of therapy.

Functional distance between recipient and donor HLA-DPB1 determines nonpermissive mismatches in unrelated HCT
Crivello et al report a novel approach to characterizing HLA-DPB1 mismatches between donor and recipient that are better tolerated than others after hematopoietic cell transplantation from unrelated volunteer donors.

TNFRSF14 aberrations in follicular lymphoma increase clinically significant allogeneic T-cell responses
This study by Kotsiou et al furnishes a proof of concept indicating that variations in tumor biology (in this case mutations of TNFSFR14) play a role in alloreactivity, potentially resulting in a significant therapeutic impact.

Patterns of expression of factor VIII and von Willebrand factor by endothelial cell subsets in vivo
A technically challenging analysis of various endothelial cell types involved in factor VIII synthesis by Pan and coworkers supports the notion that lymphatic endothelial cells produce circulating FVIII but not von Willebrand factor.

Moving treatment-free remission into mainstream clinical practice in CML
In a Perspective, Hughes and Ross explore the criteria and strategies for appropriate and safe cessation of tyrosine kinase inhibitor treatment in chronic myeloid leukemia (CML) in clinical practice.

Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency
Cicalese and colleagues report excellent medium-term survival and immune reconstitution outcomes for patients with adenosine deaminase–deficient severe combined immunodeficiency after gene therapy with a retroviral gene vector.

 

This week's complete table of contents

Why Submit to Blood?

Join the "This Week in Blood" mailing list by filling out the form below and clicking Subscribe!
*Email Address:
*First Name:
*Last Name:

 

Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.